|
1
|
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
|
J Clin Oncol
|
2005
|
3.62
|
|
2
|
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.
|
Mol Cancer Res
|
2011
|
3.25
|
|
3
|
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
|
J Clin Oncol
|
2005
|
2.77
|
|
4
|
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
|
J Am Coll Surg
|
2009
|
1.46
|
|
5
|
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.
|
Breast Cancer Res Treat
|
2009
|
1.46
|
|
6
|
Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.
|
J Clin Oncol
|
2010
|
1.20
|
|
7
|
Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
0.95
|
|
8
|
Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.92
|
|
9
|
Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer.
|
Breast Cancer Res Treat
|
2015
|
0.88
|
|
10
|
Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy.
|
Support Care Cancer
|
2014
|
0.83
|
|
11
|
Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer.
|
Ann Surg
|
2008
|
0.81
|
|
12
|
Symptom communication in breast cancer: relationships of holding back and self-efficacy for communication to symptoms and adjustment.
|
J Psychosoc Oncol
|
2013
|
0.77
|
|
13
|
Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute.
|
J Natl Compr Canc Netw
|
2014
|
0.75
|